HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: fj.07-8627revv1 fj.07-8627revv2 22/5/1296    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Amit, T. Articles by Mandel, S. PubMed PubMed Citation Articles by Amit, T. Articles by Mandel, S.

Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

Eve Topf Center of Excellence for Neurodegenerative Diseases Research, Department of Pharmacology, Faculty of Medicine, Technion, Faculty of Medicine, Haifa, Israel

¹Correspondence: Department of Pharmacology, Technion-Faculty of Medicine, P.O.B. 9697, 31096 Haifa, Israel. E-mail: youdim{at}tx.technion.ac.il

Dysregulation of brain iron homeostasis is central to early neuropathological events in Alzheimer’s disease (AD), including oxidative stress, inflammatory processes, amyloid deposition, tau phosphorylation, and neuronal cell cycle regulatory failure, leading to apoptosis. Also, there is a direct link between iron metabolism and AD pathogenesis, demonstrated by the presence of an iron-responsive element in the 5' UTR of the amyloid precursor protein transcript. As a consequence of these findings, a new paradigm is emerging that includes the development of iron-chelating neuroprotective-neurorescue drugs with multimodal functions, acting at various pathological brain targets. This concept is challenging the widely held assumption that "silver bullet" agents are superior to "dirty drugs" in drug therapy for neurodegenerative diseases. At best, the so-called magic bullets exhibit moderate symptomatic activity without modifying the course of disease progression. The present review elaborates on conventional and novel therapeutic targets of various multifunctional iron-chelating drugs (e.g., chemically designed compounds; natural polyphenols) that address multiple central nervous system etiologies in AD, aimed at preventing or slowing disease evolution. A similar approach in drug design is being investigated for treatment of cancer, AIDS, cardiovascular diseases, and depression.—Amit, T., Avramovich-Tirosh, Y., Youdim, M. B. H. Mandel, S. Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.

Key Words: cell cycle • neurodegenerative diseases • APP mRNA • multifunctional drugs